TABLE 4.
RDV and GS-441524 potencies against recombinant SARS-CoV-2 harboring prevalent Nsp12 substitutions
| Recombinant virus | RDV (n = 2–6) |
GS-441524 (n = 2) |
||
|---|---|---|---|---|
| Mean EC50 ± SD (nM)a | Mean fold change ± SD from WA1b | Mean EC50 ± SD (nM)a | Mean fold change ± SD from WA1b | |
| WA1-Nluc | 80 ± 21 | 1.0 | 1,880 ± 40 | 1.0 |
| P323L | 71 ± 26 | 0.95 ± 0.42 | 1,580 ± 370 | 0.84 ± 0.21 |
| P323L/G671S | 104 ± 20 | 1.22 ± 0.31 | 3,450 ± 1,400 | 1.83 ± 0.71 |
| WA1-Fluc | 99 ± 2 | 1.0 | 2,230 ± 380 | 1.0 |
| F694Y | 112 ± 2 | 1.14 ± 0.01 | 2,250 ± 380 | 1.04 ± 0.34 |
| P323L/F694Y | 63 ± 4 | 0.63 ± 0.03 | 1,620 ± 180 | 0.73 ± 0.04 |
a
Values are the mean ± SD of the results from independent experiments. n represents the number of replicate experiments.
b
A fold change was calculated for each experiment, and the mean fold change ± SD was calculated with these values.